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Regular Article
PLATELETS AND THROMBOPOIESIS
Platelet hyaluronidase-2 regulates the early stages of
inflammatory disease in colitis
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Platelets are specialized cells essential for hemostasis that also function as crucial effectors
capable of mediating inflammatory and immune responses. These sentinels continually
survey their environment and discriminate between homeostatic and danger signals such
as modified components of the extracellular matrix. The glycosaminoglycan hyaluronan
(HA) is a major extracellular matrix component that coats the vascular lumen and, under
normal conditions, restricts access of inflammatory cells. In response to tissue damage, the
endothelial HA matrix enhances leukocyte recruitment and regulates the early stages of
the inflammatory response.We have shown that platelets can degradeHA from the surface
of activated endothelial cells via the enzyme hyaluronidase-2 (HYAL2) and that HYAL2
is deficient in platelets isolated from patients with inflammatory bowel disease (IBD).
Platelets are known to be involved in the pathogenesis of several chronic disease states,
including IBD, but they have been largely overlooked in the context of intestinal in-
flammation. We therefore wanted to define the mechanism by which platelet HYAL2 regulates the inflammatory
response during colitis. In this study, we provide evidence that HA catabolism is disrupted in human intestinal mi-
crovascular endothelial cells isolated from patients with IBD. Furthermore, mice deficient in HYAL2 are more sus-
ceptible to an acute model of colitis, and this increased susceptibility is abrogated by transfusion of HYAL2-competent
platelets. Finally, we show that platelets, via HYAL2-dependent degradation of endothelial HA, regulate the early
stages of inflammation in colitis by limiting leukocyte extravasation. (Blood. 2019;134(9):765-775)
Introduction
Inflammatory bowel disease (IBD) is a chronic relapsing disorder
comprising 2 main subtypes, ulcerative colitis (UC) and Crohn’s
disease (CD), with different clinical manifestations but both ulti-
mately leading to relentless destruction of the gastrointestinal tract.
The pathogenesis of IBD is multifactorial, in which interactions
between genetic and environmental factors promote immuno-
regulatory dysfunction and result in chronic inflammation.1,2 Evi-
dence from animal models and human studies show that IBD
involves not only dysregulated immune cells but is also driven by
complex interactions between cell types, including the intestinal
microvasculature and platelets.3,4
A growing body of evidence shows that platelets play direct
roles in the immune response and inflammatory cascade.5
Platelet abnormalities are a well-established clinical feature of
IBD, in which the blood of patients exists in a hypercoagulable
state.6,7 Increased platelet number and reactivity associate with
serologic disease markers in IBD, and platelets are known to
circulate in an activated state.8-11 Several platelet surface glyco-
protein receptors are altered in IBD, and our laboratory found that
the extracellular matrix (ECM)-degrading enzyme hyaluronidase-2
(HYAL2) is deficient in platelets isolated from patients with
IBD.9,12,13
Tissue damage and bleeding are consistent features of IBD
progression, and remodeling of ECM molecules are strongly
implicated in IBD pathogenesis.14-16 The glycosaminoglycan
hyaluronan (HA) is widely distributed in the ECM of many tissues
and plays key roles in inflammation.17 HYAL2 belongs to a family
of hyaluronidases18 but is unique in that it is the only member
expressed in platelets and megakaryocytes, where it plays a role
in proplatelet formation.18-20 HYAL2, a glycophosphatidylinositol-
anchored protein, is packaged within a subset of platelet a
granules and, uponplatelet activation, is translocated to the platelet
surface where it functions with coreceptors to digest HA.12,21
A dynamic glycocalyx comprising HA and other membrane-bound
glycoconjugates lines the endothelial surface and restricts immune
cell access under normal conditions.22 Inflammatory stimuli en-
hanceHA synthesis andpromote the formation of a formofHA that
is covalently modified with the heavy chains (HCs) from the serum
proteoglycan inter-a-trypsin inhibitor (IaI).23 Importantly, HA pro-
duced on the luminal surface of inflamedmicrovascular endothelial
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cells plays a key role in the adhesion and extravasation of immune
cells in multiple sclerosis, liver disease, and IBD.24-29
The current article defines a novel mechanism whereby platelets
are capable of limiting leukocyte extravasation during the early
stages of colitis by degrading HA on the endothelial cell surface.
We show that mice deficient in the enzyme HYAL2 are more
susceptible to dextran sodium sulfate (DSS)-induced colitis and
that this increased susceptibility can be reversed by restoring
HYAL2 activity in platelets. Furthermore, we show that platelets
incubated with inflamed human microvascular endothelial cells
(HIMECs) are capable of reducing leukocyte extravasation via an
HYAL2-dependent mechanism and that this pathway is dis-
rupted in platelets isolated from patients with IBD.
Methods
Human tissue, cell isolation, and culture
Human intestinal tissue was obtained from the Department of
Surgical Pathology at the Cleveland Clinic (Cleveland, OH). All
specimens were of colonic origin, and diagnoses were confirmed
by using clinical criteria. Tissues were obtained from histologically
normal, noninflamed large-bowel specimens (non-IBD controls)
from patients admitted for bowel resection because of conditions
that included colon cancer, benign polyps, diverticulitis, and
colonic inertia. HIMECs were isolated and cultured as previously
reported.30,31 The study was approved by the Institutional Review
Board of the Cleveland Clinic.
DSS-induced colitis
Colitis was induced in wild-type (WT) and HYAL2 null mice by
supplying sterile acidified water with or without the addition of
2.5% DSS (MP Biomedicals, Solon, OH) ad libitum in water
bottles. All mice were weighed and monitored daily for signs of
colitis. Animals were euthanized on days 0, 4, or 7. Serum was
collected by cardiac puncture. The large intestine from the
cecum to the rectum was dissected and measured for length;
1 cm regions were taken from the terminal ileum, proximal,
transverse, and distal colon and fixed in 10 times tissue volume
of molecular biology grade Histochoice (MilliporeSigma, St.
Louis, MO).
Platelet transfusion
Mouse blood was collected from the retro-orbital plexus into
anticoagulant citrate dextrose solution. Platelet-rich plasma was
obtained by centrifugation at 100g for 8 minutes followed by
centrifugation of platelet-rich plasma at 700g in the presence of
prostacyclin (2 mg/mL) for 5 minutes at room temperature. After
washing once, platelets were resuspended in modified Tyrode’s
buffer (137 mM NaCl, 0.3 mM Na2HPO4, 2 mM KCl, 12 mM
NaHCO3, 5 mMN-2-hydroxyethylpiperazine-N9-2-ethanesulfonic
acid, 5 mM glucose, pH 7.3). Platelets from WT or HYAL2 knock-
out (KO) donor mice were pooled, and the platelet count was
adjusted to 4 3 109 platelets/mL. Recipient mice were injected
with 200 mL via the retro-orbital plexus.
Platelet coculture trans-endothelial migration assay
The upper surface of 5.0 mm pore size Transwell filters were
coated with fibronectin (Thermo Fisher Scientific, Waltham, MA)
for 1 hour, rinsed with phosphate-buffered saline, and seeded
with HIMECs to confluency in EGM-2 medium (Lonza, Basel,
Switzerland) and cultured for 5 days at 37°C to allow for tight
junction formation. HIMECs were pretreated with or without
tumor necrosis factor‐a (TNF‐a) (10 ng/mL, 16 hours) with or
without platelets (1 3 107 platelets, 1 hour) with or without
Streptomyces hyaluronidase (1 mU/mL, 30 minutes) and washed
to remove treatments. In some cases, platelets were pretreated
with anti-HYAL2 antibody (25 mg/mL; Abcam, Cambridge,
United Kingdom) or control immunoglobulin G (25 mg/mL).
Freshly isolated human peripheral blood mononuclear cells
(PBMCs) from healthy donors were labeled with Calcein AM
2 mM (1 hour on ice; Thermo Fisher Scientific) in phosphate-
buffered saline containing 1% fetal bovine serum, washed,
resuspended in RPMI 1640 containing 1% fetal bovine serum,
and added (1 3 106 PBMCs per well) to HIMECs. Chemokine
(C-C motif) ligand 5 (CCL5) was added to the lower chamber as
a chemoattractant. Transmigration was allowed to proceed for
3 hours at 37°C. Calcein AM–labeled PBMCs in the lower wells
after 3 hours were analyzed by using an automated Leica
fluorescence microscope at 203 magnification in well-scan
mode (Leica Biosystems, Buffalo Grove, IL), and the number
of transmigrated PBMCs in each well was determined by using
Image-Pro Plus software (Media Cybernetics, Rockville, MD).
Mice, microscopy, immunoblots, and HA analysis
Detailed protocols for mouse procedures, microscopy, immu-
noblots, and HA analysis are provided in the supplemental Data
(available on the Blood Web site).
Results
HYAL2 KO mice are highly susceptible to
DSS-induced colitis
Our previous studies showed that HA accumulates within
inflamed intestinal tissue of patients with IBD and mice sub-
jected to experimental models of colitis.19,27,32 HA deposition is
an early event that precedes inflammation in the DSS-induced
colitis model,26,27 and we hypothesized that defects in HA
turnover might accelerate disease progression. Mice supplied
with DSS in drinking water reproducibly develop colitis in a time-
and concentration-dependent manner.33 DSS treatment com-
promises the epithelial barrier, leading to a bacterially induced
colitis, and pathology is first observed in the distal colon where
bacterial burden is greatest. We initiated intestinal inflammation
by delivering 2.5% DSS in the drinking water of HYAL2-deficient
and control mice, and disease was measured over 7 days. Loss of
HYAL2 led to accelerated and increased disease, measured
according to overall weight loss (Figure 1A-B; supplemental
Figure 1A). Mice were evaluated for outward signs of disease
activity by using the disease activity index (DAI); these signs
included rectal bleeding, loose stools, ruffled fur, hunched
posture, and rectal prolapse. Our data show that HYAL2 null
mice were more severely affected (Figure 1C) compared with
control mice (n 5 10 each; P , .01). Histologic examination of
distal colon sections of unchallenged mice revealed a thicker
external muscle layer but no morphologic differences in the
colonic mucosa in HYAL2 null mice compared with control mice
(supplemental Figure 2A-B). However, after 7 days of DSS treat-
ment, increased epithelial erosion, crypt loss, angiogenesis,
submucosal swelling, and increased infiltration of immune cells
were observed in HYAL2-deficient mice compared with WT
control mice (Figure 1A,D; supplemental Figure 3). Changes in
colon length due to DSS-induced colitis are a common indicator
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of disease severity in this model, and HYAL2 KO mice also
exhibited a significantly shortened colon compared with control
mice (Figure 1E).
Platelets isolated from mice with DSS-induced
colitis have reduced HYAL2 protein and
hyaluronidase activity
IBD is intimately associated with platelet abnormalities,34 and
we hypothesized that platelets isolated from DSS-treated
mice might also exhibit reduced HA-degrading activities. We
therefore isolated platelets from mice after 7 days of DSS-
induced colitis or from untreated control mice and compared
HYAL2 protein and hyaluronidase activity. HYAL2 protein
levels were an average of 44% lower in platelets from DSS-
treated mice compared with control mice (n 5 5; P , .05)
(Figure 2A-B), and corresponding enzyme activity measurements
revealed that hyaluronidase activity was also significantly re-
duced (n 5 5; P , .05) (Figure 2C). Reactive thrombocytosis is
a known feature of IBD and DSS-induced colitis,35 and we
therefore compared circulating platelet count before and after
colitis. Despite the mild thrombocytopenia associated with
HYAL2 null mice, we observed an approximate 52% increase
in circulating platelet count after 7 days of DSS (Figure 2D).
Comparison of serum HA levels revealed a proportional increase
in circulating HA during DSS challenge between control and
HYAL2-deficient mice (Figure 2E), consistent with defects in HA
turnover.
Platelet HYAL2 regulates susceptibility of
DSS-induced colitis in mice
Because HYAL2 was deficient in platelets from patients with IBD
and from DSS-treated mice, we speculated that the interaction
between platelets and the endothelium might play a key role in
regulating inflammatory progression. To determine whether the
enhanced inflammation and tissue destruction seen in HYAL2
KO mice was due to the inability of blood cells to degrade HA,
we generated bone marrow (BM) chimeric mice and subjected
them to DSS-induced colitis for 7 days. Histologic scoring of
distal colon tissue, weight loss, and the DAI revealed that recon-
stitution of HYAL21/1 mice with HYAL22/2 BM increased suscep-
tibility to DSS-induced colitis compared with mice reconstituted
withHYAL21/1BMas a control (Figure 3; supplemental Figure 1B).
Key parameters, including submucosal swelling, epithelial ero-
sion, and immune cell infiltration (supplemental Figure 3), closely
recapitulated our previous observations of HYAL2 null mice
(Figure 1). Control mice reconstituted with HYAL22/2 BM exhibited
normal blood cell counts (supplemental Table 2) except for the
expected mild anemia and thrombocytopenia associated with
loss of HYAL2 in hematopoietic cells.36,37
We therefore sought to determine whether HYAL2 null mice
could be rescued by transplant of control BM. Unexpectedly,
irradiation was lethal for 23 of 30 healthy, untreated KO mice
























































































Figure 1. HYAL2 KOmice are more susceptible to DSS-induced colitis. (A) Cross-sections of distal colon collected from mice after 7 days of colitis induction with 2.5% DSS.
Hematoxylin-eosin staining highlights the cellular and structural changes in the intestine, including inflammatory leukocyte infiltration. Boxed regions are enlarged in adjacent
panels. Scale bars indicate 500 mm. L denotes the intestinal lumen, triangles indicate the epithelial layer, S denotes the submucosa, and arrows indicate the muscularis mucosae.
(B) Body weight wasmeasured on day 7 and comparedwith startingweight. (C)Mice were scored for outward signs of disease, includingweight loss, hunchedposture, ruffled fur,
bloody stools, and rectal prolapse. (D) Distal colon sections frommice after 7 days of DSSwere scored for pathologic changes, including erosion of the epithelial layer, leukocyte
infiltration, submucosal swelling,muscularis mucosae hyperplasia, and increased vascularization. (E) Colons frommice euthanized after 7 days of DSSweremeasured for distance
(centimeters) from the distal end of the cecum to the rectum. Symbols represent individual mice. Symbols indicate genotypes: (:) WT mice and (d) HYAL2 KO mice. Data are
reported as mean 6 SEM; n 5 10 mice per group. *P , .05.
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mice reconstituted with HYAL21/1 BM appeared to be less
severely affected by DSS (supplemental Figure 3; supplemental
Figure 4B-C), the low number of survivors made interpretation
underpowered in this model and incomplete.
We therefore directly examined the role of platelet HYAL2 in
DSS-induced colitis by adoptive transfer of platelets into KO
mice (Figure 4). Because HYAL2 KO mice do not exhibit
a consumptive thrombocytopenia,20 we were able to adjust
platelet counts to normal levels by platelet transfusion. In the
case of KO mice receiving WT platelets, ;70% of circulating
platelets contained HYAL2 at the onset of colitis. Survival of
adoptively transferred platelets was measured by using in vivo
biotinylation, and no difference in platelet life span was ob-
served (data not shown). Transfused mice were evaluated for
weight loss, the DAI, and histologic indices of disease over
7 days of DSS-induced colitis. Mice receiving adoptive transfer
of HYAL2-containing platelets exhibited protection from
weight loss, less severe signs of disease activity, and histologic
evidence of colon sparing compared with mice receiving
HYAL2-deficient platelets as a control (supplemental Figure
1C; supplemental Figure 3). Platelets from HYAL2-deficient
mice have been shown to activate and spread normally,36
and we further evaluated these platelets for a granule re-
lease and agonist response; no significant differences were
observed compared with control platelets (supplemental
Figure 5).
Platelet HYAL2 deficiency exacerbates
inflammation in mice with DSS-induced colitis
Previous studies from our laboratory have shown that TNF-a is
a potent inducer of HA on endothelial surfaces by regulation of
the enzyme hyaluronan synthase 3 (HAS3),19 and genetic knock-
out of HAS3 reduces inflammation in DSS-treated mice.26 We
therefore analyzed serum TNF-a and interleukin-6 (IL-6) in control
and DSS-treated mice (Figure 5A-B). No difference was observed
in WT or KO mice at baseline, but at day 7, levels of both TNF-a
and IL-6 were significantly increased inHYAL2KOmice compared
with WT control mice (P , .01). Transfusion of HYAL2 KO mice
with WT platelets resulted in a significant reduction in TNF-a and
IL-6 levels compared with KO alone (P , .01) or KO mice
transfused with KO platelets (P , .001).
Macrophage infiltration is increased in DSS-treated
mice with HYAL2-deficient platelets
HA accumulation begins in the microvasculature in DSS-induced
colitis and corresponds with dense regions of leukocyte in-
filtration in the inflamed crypts and submucosa of patients with
IBD.27,32 We examined immune cell infiltration by measuring
F4/801 macrophages and Ly6G1 neutrophils present in distal
colon tissue sections from control and DSS-treated mice after
7 days (supplemental Figure 6). Quantifiable regions of in-
filtration in the mucosa and submucosa of WT and HYAL2 KO

































































































Figure 2. Platelets from mice with DSS-induced colitis have reduced HYAL2 and hyaluronidase activity. Platelets were isolated from untreated control and DSS-treated
mice after 7 days. (A) Platelet lysates corresponding to 10mg of protein were probed for HYAL2 and actin. (B) Densitometry quantification shows that HYAL2 levels are reduced an
average of 44% (*P, .05) in platelets fromDSS-treatedmice compared with control mice. (C) Platelet lysates were compared for their HA-degrading activities by incubation with
60 nM Förster resonance energy transfer–based HA nanoprobes at pH 4.5. Maximum activity was achieved by recombinant hyaluronidase. Platelets from DSS-treated mice
exhibit a 60% reduction (*P, .05) in HA-degrading activity compared with platelets from untreatedmice. (D) Changes in circulating platelet count before and after DSS-induced
colitis (**P , .01). (E) Serum isolated from DSS-treated mice and control mice at 7 days was tested for HA levels (*P , .05).
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control mice (P, .01) (Figure 5C-D). Transfusion of KOmice with
WT platelets led to a 45% reduction (P, .05) in macrophage and
neutrophil staining compared with either KOmice alone or mice
receiving KO platelets.
Myeloperoxidase (MPO) activity was next measured as a marker
of neutrophils and macrophages (Figure 5E). We found no
statistically observable differences inMPO activity in colon tissue
from untreatedWT or HYAL2 KOmice; however, consistent with
the magnitude of inflammation after 7 days of DSS, MPO activity
was increased in HYAL2 KO mice compared with control mice
(P , .01). Transfusion of WT platelets into KO mice reduced
MPO activity compared with KO mice alone (P , .05) or com-
pared with mice receiving KO platelets (P , .05). Together,
these data support a role for platelet HYAL2 regulating in-
flammatory cell infiltration in DSS-induced colitis.
Deposition of leukocyte-adhesive HA-HC is
increased in HYAL2-deficient mice
In addition to its role amplifying HA production through HAS3,
TNF-a stimulates production of the enzyme TNF-stimulated
gene 6, which modifies HA into HA-HC and enhances leuko-
cyte recruitment.38Wemeasured submucosal HA-HC deposition
and found a striking increase in HA-HC in HYAL2 KO mice
compared with WT mice (Figure 6A). Quantitative analysis of
tissue HA revealed that total HA levels increased in response to
DSS in both control and HYAL2 KO mice, but transfusion of
platelets did not affect total HA levels within colon tissue
(Figure 6B). However, KOmice transfused with WT platelets had
a dramatic decrease in HA-HC deposition compared with KO
alone or mice receiving KO platelets (Figure 6C). This finding is
consistent with the reduction of TNF-a levels in serum (Figure 5A)
and abrogation of leukocyte infiltration into the tissue of HYAL2
null mice transfused with WT platelets (Figure 5C-D).
The deposition of HA-HC suggested that the microvasculature
of the colon was permeable, allowing serum, which contains IaI,
to leak into inflamed intestinal tissue. We examined vascular
permeability of the colon by i.v. injection of Evans blue dye (EB)
and measured leakage into the colon. Although there was no
difference in unchallenged mice, after 7 days of treatment with
DSS, HYAL2 KO mice displayed increased EB in colon tissue
compared with that of control mice (Figure 6D), suggesting that
the endothelium was compromised. Transfusion of control
platelets into KOmice at the onset of colitis significantly reduced
leakage of EB into the inflamed colon compared with KO mice
alone or mice receiving KO platelets.
Platelet Hyal-2 regulates leukocyte
trans-endothelial migration
A critical function of the endothelium during inflammation is to
regulate the migration of leukocytes to sites of inflammation. HA
accumulation within the colonic microvasculature of mice occurs
as early as 3 days after DSS treatment, well before inflammatory
infiltrate can be observed, where it acts to promote leukocyte
recruitment,26,27 and platelets can cleave HA from the surface of
cells in an HYAL2-dependent fashion.12,19 Within the microvas-
culature of the colon, HA modified with HCs was observed in
patients with IBD compared with non-IBD control subjects and
also within vessels of mice subjected to DSS-induced colitis
(Figure 7A; supplemental Figure 7A). To determine whether the
increase in vessel HA corresponded with changes in HYAL2, we




























































































Figure 3. Loss of HYAL2 in hematopoietic cells exacerbates DSS-induced colitis. Bone marrow transplant (BMT) chimeras were generated by using WT (HYAL21/1) and KO
(HYAL22/2) mice as host and BM donor, respectively. (A) Cross-sections of distal colon collected from mice after 7 days of 2.5% DSS. Hematoxylin-eosin staining reveals the
cellular and structural changes in the intestine, including inflammatory leukocyte infiltration. Boxed regions are enlarged in adjacent panels. Scale bars indicate 500 mm. L
denotes the intestinal lumen, triangles indicate the epithelial layer, S denotes the submucosa, and arrows indicate themuscularismucosae. (B) Body weight wasmeasured on day
7 and compared with starting weight. (C) Mice were scored for outward signs of disease, including weight loss, hunched posture, ruffled fur, bloody stools, and rectal prolapse.
(D) Distal colon sections from mice after 7 days of DSS were scored for pathologic changes, including erosion of the epithelial layer, leukocyte infiltration, submucosal swelling,
muscularis mucosae hyperplasia, and increased vascularization. (E) Colons frommice euthanized after 7 days of DSSweremeasured for distance (centimeters) from the distal end
of the cecum to the rectum. Symbols indicate genotypes and treatment: (:) WT mice receiving WT BM, n 5 8; and (s) WT mice receiving HYAL2 KO BM, n 5 7. Data are
reported as mean 6 SEM. *P , .05.
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examined cultured endothelial cells and found that messenger
RNA, HYAL2 protein, and activity were deficient in HIMECs from
patients with IBD compared with those from non-IBD control
subjects (Figure 7B-C; supplemental Figure 7B-C). We next
questioned whether TNF-a, which increases HA synthesis in
HIMECs, also regulates HYAL2. HIMECs treated with TNF-a
showed consistent decreases in HYAL2 protein, messenger
RNA, and activity levels (Figure 7D; supplemental Figure 7D-E).
These analyses reveal that HYAL2 protein levels are consistent
through passage in HIMECs and are responsive to TNF-a.
Based on these findings, we hypothesized that platelet HYAL2
regulates inflammatory progression by degrading HA on the
surface of inflamed vessels to limit leukocyte emigration. To test
this hypothesis, HIMECs were grown on Transwell filters without
or with TNF-a (10 ng/mL) in the presence of human serum to
induce formation of leukocyte-adhesive HA-HC. After activation,
HIMECs were incubated in the presence or absence of non-
activated freshly isolated platelets (1003 106 per well) for 1 hour
followed by gentle washing. An HIMEC-independent chemo-
tactic factor (CCL5; 100 ng/mL) was added to the bottom well
before the addition of human peripheral blood mononuclear
cells (PBMCs) to the upper chamber, and transmigration was
measured by analyzing the number of PBMCs present in the
bottom chamber after 3 hours (Figure 7E). Stimulation of HIMECs
with TNF-a led to an increase in transmigration (P , .001). Pre-
incubation of HIMECs with platelets also increased migration but
to a lesser extent (P, .05) compared with untreated control cells.
Preincubation of TNF-stimulated HIMECs with platelets de-
creased migration an average of 35% (P , .001) compared with
TNF-stimulated HIMECs without platelet treatment.
To test whether the observed decrease in migration was due to
the activity of HYAL2, we treated platelets with an HYAL2-
neutralizing antibody or with nonspecific control immunoglob-
ulin G and removed excess antibody by centrifugation. PBMC
transmigration across TNF-stimulated HIMEC cultures pre-
incubated with the HYAL2-blocked platelets was equivalent to
leukocyte migration across TNF-stimulated HIMECs alone.
Control immunoglobulin G–treated platelets did not abrogate
PBMC migration and were as effective as untreated platelets
(data not shown). These findings indicate that platelets can re-
duce PBMC transmigration across an activated HIMEC mono-
layer through an HYAL2-dependent mechanism. We further
assayed HA release into the media from replicate cultures of
HIMECs and observed that incubation of TNF-stimulated
HIMECs with platelets results in increased media HA (P , .001),
which can be significantly inhibited by pretreating platelets with
an HYAL2-neutralizing antibody (Figure 7F). This scenario sug-
gests that platelets can limit PBMC transmigration by releasing
HA from the surface of activated HIMECs.
We previously reported that platelets isolated from patients
with IBD exhibit a 45% reduction in HYAL2 protein levels and
a corresponding decrease in hyaluronidase activity.12 To de-
































































































































Figure 4. PlateletHYAL2mediates susceptibility to colitis.Mice received adoptive transfer of 83 108WTor KOplatelets as indicated at the onset of DSS treatment. (A) Cross-
sections of distal colon collected from mice after 7 days of 2.5% DSS. Hematoxylin-eosin staining reveals the cellular and structural changes in the intestine, including in-
flammatory leukocyte infiltration. Boxed regions are enlarged in adjacent panels. Scale bars indicate 500 mm. L denotes the intestinal lumen, triangles indicate the epithelial
layer, S denotes the submucosa, and arrows indicate the muscularis mucosae. (B) The percentage of platelets expressing HYAL2 in KOmice receiving WT platelets assessed by
using flow cytometry. (C) Body weight was measured on day 7 and compared with starting weight. (D) Mice were scored for outward signs of disease, including weight loss,
hunched posture, ruffled fur, bloody stools, and rectal prolapse. (E) Distal colon sections frommice after 7 days of DSS were scored for pathologic changes, including erosion of
the epithelial layer, leukocyte infiltration, submucosal swelling, muscularis mucosae hyperplasia, and increased vascularization. (F) Colons from mice euthanized after 7 days of
DSS were measured for distance (centimeters) from the distal end of the cecum to the rectum. Symbols indicate genotypes and treatment: (=) KO mice transfused with WT
platelets, n 5 8; and (♦) KO mice transfused with KO platelets, n 5 8. Data are reported as mean 6 SEM. *P , .05; **P , .01.
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regulate leukocyte transmigration, we compared unstimulated,
freshly isolated platelets from healthy donor subjects and from
patients with IBD (at least 6 each) using the same trans-endothelial
migration assay. As shown in Figure 7G, preincubation of TNF-
stimulated HIMECs with platelets from patients with IBD resulted
in substantially increased (average 130% of control; P , .05)
PBMC migration compared with HIMECs treated with platelets
from healthy donor subjects. This finding suggests that the
platelet HYAL2-dependent mechanism is disrupted in the IBD
patient population and may result in sustained expression of
leukocyte-adhesive HA-HC by the microvasculature, impairing
the resolution of inflammation and promoting further tissue
damage.
Discussion
Using a combination of patient tissues, animal models, and
patient cells, we provide evidence that platelets regulate the
early stages of inflammation by limiting leukocyte extravasation
via HYAL2-dependent degradation of endothelial HA. We show
that loss of HYAL2 in mice exacerbated disease activity in the
DSS-induced experimental colitis model. Importantly, we found
that increased susceptibility to DSS-induced colitis in the HYAL2-
KO background can be significantly abrogated by transfusion of
platelets expressing HYAL2 at the initiation of colitis, and that
this effect occurs in the microvasculature. We also show for the
first time that HYAL2 is deficient in cultured intestinal endothelial
cells isolated from patients with IBD and that mice subjected to
DSS-induced colitis have diminished platelet-HYAL2 and hyal-
uronidase activity similar to the IBD patient platelets. We found
that this protective mechanism in platelets is HYAL2 dependent
and impaired in platelets isolated from patients with IBD. Finally,
these animal model data reveal that platelet HYAL2 is a protective
mechanism controlling colitis, and that HYAL2-competent platelet
supplementation for patients with IBD presents an unanticipated
opportunity to investigate a new arm of treatment to add to the
current modalities.
A growing number of studies underscore the importance of
nonimmune cells such asmesenchymal, endothelial, and platelets
as key players in the progression of IBD inflammatory cascade.1,4
The results of the current investigation highlight the interplay
between platelets and the microvasculature during the early
stages of colitis. HA accumulates in small vessels at the early
stages of pathologic changes in the inflamed distal colon
before inflammatory cell infiltration,27 and HA supports leu-
kocyte and platelet adhesion, as shown in vitro.32,39,40 Here, we

























































































































Figure 5. Platelet HYAL2 regulates serum inflammatory cytokines and inflammatory leukocyte infiltration in mice with DSS-induced colitis. Serum isolated from DSS-
treated and control mice at 7 days was tested for (A) TNF-a and (B) IL-6 by using an enzyme-linked immunosorbent assay. (C) F4/80-positive area expressed as the percentage of
total area. (D) Ly6G-positive area expressed as the percentage of total area. (E) MPO activity was measured in distal colon lysates of untreated and DSS-treated mice with or
without platelet transfusion at 7 days. Data are reported as mean 6 SEM; n 5 10 mice per group. *P , .05; **P , .01; ***P , .001.
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microvascular endothelial cells isolated from patients with IBD at
the messenger RNA level, with a corresponding deficiency in
HYAL2 protein and HA degradation activity (Figure 7B-C;
supplemental Figure 7B-C). Our data reveal that in response to
TNF-a, HYAL2 becomes downregulated (Figure 7D; supple-
mental Figure 7D-E), supporting previous observations that
conditions which promote production of proinflammatory
HA may also suppress hyaluronidase activity.41 We previously
reported that HIMECs isolated from patients with IBD over-
produce leukocyte-adhesive HA compared with HIMECs isolated
from healthy control subjects.19 This observation is consistent with
reports that HYAL2 acts as a negative regulator of the glycocalyx42
such that the reduced HYAL2 in IBD HIMECs would result in
increased cell surface HA. Unstimulated HIMECs isolated from
patients with IBD support greater leukocyte adhesion compared
with HIMECs from non-IBD control subjects,43 and increased HA
may contribute.
The ability of inflammation-associated modification of ECM (ie,
HA-HC) to enhance leukocyte recruitment is a general mechanism
relevant in many disease states beyond IBD.24-29 HA via its in-
teraction with CD44 plays a crucial for leukocyte infiltration
into inflammatory sites, and multiple studies show that dis-
ruption of this interaction by genetic ablation,24,44 CD44 an-
tibody blockade,29,39,45,46 or digestion of cell surface HA with
hyaluronidase28,47 is capable of abolishing HA-dependent cell
adhesion. Although other HA receptors may also play a role in
this process, to date, CD44 is the most extensively studied.
Consistent with our studies, early administration of recombi-
nant human hyaluronidase before signs of disease activity
occur has been shown to inhibit reactive adipogenesis, in-
flammation, and tissue injury in a mouse DSS model.48 To the
best of our knowledge, our report is the first to show that
platelets can regulate this process and also that circulating cells
rather than a soluble enzyme are mediators.
Our data raise several intriguing questions regarding the role
of HA in the initiation and perpetuation of inflammation. We
previously recognized that disruption of HA synthesis by HAS3





















































































Figure 6. Microvascular permeability is increased in mice with DSS-induced colitis with HYAL2-deficient platelets. (A) Distal colon sections from mice treated with 2.5%
DSS for 7 days with or without transfusion of platelets were evaluated for HA-HC by immunostaining for HA (green) and the HCs of IaI (red) and counterstained with 49,6-
diamidino-2-phenylindole for nuclei. L denotes the lumen. Lower panels show the submucosal regions at higher magnification. Images are representative of at least 8 mice. (B)
Measurement of HA levels in colon tissue from control, DSS-treated mice, and DSS-treated mice receiving platelets. (C) Quantification of colocalization of HA with HCs of IaI as
a measurement of HA-HC deposition. (D) Measurement of EB extracted from distal colon tissue of mice treated with or without 2.5% DSS. Data are reported as mean6 SEM;
n5 10 mice per group. *P, .05; **P, .01; ***P, .001. Imaging, detection, and software details: TCS SP5 II confocal/multiphoton high-speed upright microscope, HCX PL APO
40X/1.25NA oil immersion objective, HyD system detector, and LAS AF software (all Leica Biosystems). Pearson’s correlation coefficients were obtained by analyzing indi-
vidual images (layers) of the Z-stack with Image-Pro Plus software.
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model of colitis.26 We now understand that disruption of HA turn-
over in mice by either systemic deletion of HYAL2 or generation
of HYAL2 null BM chimeras increases susceptibility to DSS-
induced colitis (Figure 5). The finding that HYAL2 is deficient
in IBD platelets and HIMECs, and in mouse platelets during
experimental colitis, was unexpected. HAS3 is induced by
TNF-a,26 and in HIMECs, it also leads to downregulation of HYAL2
(Figure 7D; supplemental Figure 7D-E); however, the data
available for HYAL2 in other cell types are contradictory41,49,50
and may reflect cell type–specific responses. Our data suggest
that HAS3 and HYAL2 may be regulated in a temporal fashion
in response to inflammation, such that HA functions to recruit
immune cells and HYAL2 acts to limit inflammation to enable
resolution.
Although our data describe an early, protective role for platelets in
colitis, it is likely that platelets exacerbate inflammation later in the
disease. Many proinflammatory functions of platelets have been
noted in IBD, and HA fragments released from the surface of
inflamed cells can activate monocytes, endothelial cells, and
smooth muscle cells.19 Whether those fragments reach concen-
trations that can signal in circulation or locally at the site of their
generation is not known. At extravascular sites of platelet accu-
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Figure 7. Platelet HYAL2 regulates trans-endothelial PBMC migration. (A) Representative microvessels present in colon tissues isolated from non-IBD control subjects,
patients with IBD, and WT or HYAL2 KO mice subjected to DSS-induced colitis were evaluated for HA-HC by immunostaining for HA (green) and the HCs of IaI (red) and
counterstained with 49,6-diamidino-2-phenylindole for nuclei. Arrows indicate HA glycocalyx structures extending from the vessel surface. (B) Quantitative real-time
polymerase chain reaction analysis of HYAL2 expression of HIMECs isolated from non-IBD and IBD patient surgical specimens (n 5 8 each; **P , .01). (C) Representative
immunoblots analyzing HYAL2 levels in HIMECs isolated from non-IBD and IBD patient surgical specimens (n5 8 each). Lysates were normalized to total protein (25 mg), and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. (D) HIMECs were cultured with or without TNF‐a for 16 hours and evaluated for HYAL2
by using immunoblot over multiple passages. (E) HIMECs were seeded on permeable supports (3 mmpore size) placed into a 24-well plate, and grown to confluence. HIMECs
were treated with or without TNF‐a for 16 hours at 37°C to promote leukocyte-adhesive HA-HC formation. Following activation, HIMECs were incubated in the presence or
absence of nonactivated freshly isolated human platelets (1003 106 per well) for 1 hour at 37°C. In some experiments, HIMECs were treated with Streptomyces hyaluronidase
or with platelets preincubated with an HYAL2-blocking antibody as indicated. CCL5 (100 ng/mL) was added to the bottom well, and Calcein AM–labeled PBMCs (13 106 per
well) were added to the upper chamber. (F) HIMECs were cultured with or without TNF-a to induce HA-HC formation on the cell surface. Cultures were then washed and
incubated in the presence or absence of platelets as indicated. HA released into the media was measured by using an enzyme-linked immunosorbent assay–like method, and
the data represent 3 independent experiments. (G) TNF-a–stimulated HIMECs were pretreated with platelets isolated from IBD platelets or non-IBD control subjects before
PBMC trans-endothelial migration. Data are reported as mean 6 SEM; n 5 4 independent experiments of at least 6 patients each. Values with different alphabetical
superscripts are significantly different from each other (P , .05); *P , .05. Image, detection, and software details: TCS SP5 II confocal/multi-photon high-speed upright
microscope, HCX PL APO340/1.25NA oil immersion objective, HyD system detector, and LAS AF software (all Leica Biosystems). Scale bar: 25 mm. Data acquisition details:
Calcein AM–labeled PBMCs were detected in the lower wells with an automated Leica DM inverted microscope at 203 magnification set to well-scan mode. PBMCs were
enumerated on the basis of fluorescence and size by using Image-Pro Plus acquisition software.
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platelets and HA fragments reach concentrations capable of driving
a self-perpetuating loop that contributes to inflammatory disease.
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10. Järemo P, Sandberg-Gertzen H. Platelet
density and size in inflammatory bowel dis-
ease. Thromb Haemost. 1996;75(4):560-561.
11. Morowitz DA, Allen LW, Kirsner JB.
Thrombocytosis in chronic inflammatory
bowel disease. Ann Intern Med. 1968;68(5):
1013-1021.
12. Albeiroti S, Ayasoufi K, Hill DR, Shen B, de la
Motte CA. Platelet hyaluronidase-2: an en-
zyme that translocates to the surface upon
activation to function in extracellular matrix
degradation. Blood. 2015;125(9):1460-1469.
13. Danese S, de la Motte C, Sturm A, et al.
Platelets trigger a CD40-dependent in-
flammatory response in the microvasculature
of inflammatory bowel disease patients.
Gastroenterology. 2003;124(5):1249-1264.
14. Petrey AC, de la Motte CA. The extracellular
matrix in IBD: a dynamic mediator of in-
flammation. Curr Opin Gastroenterol. 2017;
33(4):234-238.
15. Shimshoni E, Yablecovitch D, Baram L, Dotan
I, Sagi I. ECM remodelling in IBD: innocent
bystander or partner in crime? The emerging
role of extracellular molecular events in sus-
taining intestinal inflammation. Gut. 2015;
64(3):367-372.
16. Mortensen JH, Godskesen LE, Jensen MD,
et al. Fragments of citrullinated and MMP-
degraded vimentin and MMP-degraded type
III collagen are novel serological biomarkers to
differentiate Crohn’s disease from ulcerative
colitis. J Crohn’s Colitis. 2015;9(10):863-872.
17. Petrey AC, de la Motte CA. Hyaluronan,
a crucial regulator of inflammation. Front
Immunol. 2014;5(MAR):101.
18. Csoka AB, Frost GI, Stern R. The six
hyaluronidase-like genes in the human and
mouse genomes. Matrix Biol. 2001;20(8):
499-508.
19. de la Motte C, Nigro J, Vasanji A, et al.
Platelet-derived hyaluronidase 2 cleaves
hyaluronan into fragments that trigger
monocyte-mediated production of proin-
flammatory cytokines. Am J Pathol. 2009;
174(6):2254-2264.
20. Petrey AC, Obery DR, Kessler SP, Flamion B,
de la Motte CA. Hyaluronan depolymerization
by megakaryocyte hyaluronidase-2 is required
for thrombopoiesis. Am J Pathol. 2016;186(9):
2390-2403.
21. Andre B, Duterme C, Van Moer K, Mertens-
Strijthagen J, Jadot M, Flamion B. Hyal2 is
a glycosylphosphatidylinositol-anchored, lipid
raft-associated hyaluronidase. Biochem Bio-
phys Res Commun. 2011;411(1):175-179.
22. Reitsma S, Slaaf DW, Vink H, van Zandvoort
MA, oude Egbrink MG. The endothelial
glycocalyx: composition, functions, and visu-
alization. Pflugers Arch. 2007;454(3):345-359.
23. Milner CM, Tongsoongnoen W, Rugg MS,
Day AJ. The molecular basis of inter-
alpha-inhibitor heavy chain transfer on to
hyaluronan. Biochem Soc Trans. 2007;
35(pt 4):672-676.
24. McDonald B, McAvoy EF, Lam F, et al.
Interaction of CD44 and hyaluronan is the
dominant mechanism for neutrophil seques-
tration in inflamed liver sinusoids. J Exp Med.
2008;205(4):915-927.
25. Bandyopadhyay SK, de la Motte CA, Kessler
SP, Hascall VC, Hill DR, Strong SA.
Hyaluronan-mediated leukocyte adhesion
and dextran sulfate sodium-induced colitis are
attenuated in the absence of signal transducer
and activator of transcription 1. Am J Pathol.
2008;173(5):1361-1368.
26. Kessler SP, Obery DR, de la Motte C.
Hyaluronan synthase 3 null mice exhibit de-
creased intestinal inflammation and tissue
damage in the DSS-induced colitis model. Int
J Cell Biol. 2015;2015:745237.
27. Kessler S, Rho H, West G, Fiocchi C, Drazba J,
de la Motte C. Hyaluronan (HA) deposition
precedes and promotes leukocyte re-
cruitment in intestinal inflammation. Clin
Transl Sci. 2008;1(1):57-61.
28. Winkler CW, Foster SC, Matsumoto SG, et al.
Hyaluronan anchored to activated CD44 on
central nervous system vascular endothelial
cells promotes lymphocyte extravasation in
experimental autoimmune encephalomyelitis.
J Biol Chem. 2012;287(40):33237-33251.
29. Guidotti LG, Inverso D, Sironi L, et al.
Immunosurveillance of the liver by in-
travascular effector CD8(1) T cells. Cell. 2015;
161(3):486-500.
30. Binion D,West G, Ina K, Ziats NP, Emancipator
SN, Fiocchi C. Enhanced leukocyte binding by
intestinal microvascular endothelial cells in
inflammatory bowel disease.
Gastroenterology. 1997;112(6):1895-1907.
31. Vogel JD, West G, Danese S, et al. CD40-
mediated immune-nonimmune cell




 http://ashpublications.org/blood/article-pdf/134/9/765/1554331/blood893594.pdf by guest on 08 M
arch 2021
interactions induce mucosal fibroblast che-
mokines leading to T-cell transmigration.
Gastroenterology. 2004;126(1):63-80.
32. de la Motte CA, Hascall VC, Drazba J,
Bandyopadhyay SK, Strong SA. Mononuclear
leukocytes bind to specific hyaluronan struc-
tures on colon mucosal smooth muscle cells
treated with polyinosinic acid:polycytidylic
acid: inter-alpha-trypsin inhibitor is crucial to
structure and function. Am J Pathol. 2003;
163(1):121-133.
33. Hibi T, Ogata H, Sakuraba A. Animal models
of inflammatory bowel disease.
J Gastroenterol. 2002;37(6):409-417.
34. Danese S, Papa A, Saibeni S, Repici A,
Malesci A, Vecchi M. Inflammation and co-
agulation in inflammatory bowel disease: the
clot thickens. Am J Gastroenterol. 2007;
102(1):174-186.
35. Yan SL, Russell J, Harris NR, Senchenkova EY,
Yildirim A, Granger DN. Platelet abnormalities
during colonic inflammation. Inflamm Bowel
Dis. 2013;19(6):1245-1253.
36. Onclinx C, Dogne S, Jadin L, et al. Deficiency
in mouse hyaluronidase 2: a new mechanism
of chronic thrombotic microangiopathy.
Haematologica. 2015;100(8):1023-1030.
37. Jadin L, Wu X, Ding H, et al. Skeletal and
hematological anomalies in HYAL2-deficient
mice: a second type of mucopolysaccharidosis
IX? FASEB J. 2008;22(12):4316-4326.
38. Day AJ, de la Motte CA. Hyaluronan cross-link-
ing: a protective mechanism in inflammation?
Trends Immunol. 2005;26(12):637-643.
39. de La Motte CA, Hascall VC, Calabro A,
Yen-Lieberman B, Strong SA. Mononuclear
leukocytes preferentially bind via CD44 to
hyaluronan on human intestinal mucosal
smooth muscle cells after virus infection or
treatment with poly(I.C). J Biol Chem. 1999;
274(43):30747-30755.
40. Petrey AC, de la Motte CA. Thrombin cleav-
age of inter-a-inhibitor heavy chain 1 regu-
lates leukocyte binding to an inflammatory
hyaluronan matrix. J Biol Chem. 2016;291(47):
24324-24334.
41. Selbi W, de la Motte CA, Hascall VC, Day AJ,
Bowen T, Phillips AO. Characterization
of hyaluronan cable structure and function
in renal proximal tubular epithelial cells.
Kidney Int. 2006;70(7):1287-1295.
42. Duterme C, Mertens-Strijthagen J, Tammi M,
Flamion B. Two novel functions of
hyaluronidase-2 (Hyal2) are formation of the
glycocalyx and control of CD44-ERM inter-
actions. J Biol Chem. 2009;284(48):
33495-33508.
43. Binion DG, West GA, Volk EE, et al. Acquired
increase in leucocyte binding by intestinal
microvascular endothelium in inflammatory
bowel disease. Lancet. 1998;352(9142):
1742-1746.
44. Teder P, Vandivier RW, Jiang D, et al.
Resolution of lung inflammation by CD44.
Science. 2002;296(5565):155-158.
45. Aruffo A, Stamenkovic I, Melnick M, Underhill
CB, Seed B. CD44 is the principal cell surface
receptor for hyaluronate. Cell. 1990;61(7):
1303-1313.
46. DeGrendele HC, Estess P, Siegelman MH.
Requirement for CD44 in activated T cell ex-
travasation into an inflammatory site. Science.
1997;278(5338):672-675.
47. Huang Z, Zhao C, Chen Y, et al. Recombinant
human hyaluronidase PH20does not stimulate an
acute inflammatory response and inhibits
lipopolysaccharide-induced neutrophil re-
cruitment in the air pouchmodel of inflammation.
J Immunol. 2014;192(11):5285-5295.
48. Dokoshi T, Zhang LJ, Nakatsuji T, et al.
Hyaluronidase inhibits reactive adipogenesis
and inflammation of colon and skin. JCI In-
sight. 2018;3(21):123072.
49. Monzón ME, Manzanares D, Schmid N,
Casalino-Matsuda SM, Forteza RM.
Hyaluronidase expression and activity is reg-
ulated by pro-inflammatory cytokines in hu-
man airway epithelial cells. Am J Respir Cell
Mol Biol. 2008;39(3):289-295.
50. Sherman LS, Matsumoto S, SuW, Srivastava T,
Back SA. Hyaluronan synthesis, catabolism,
and signaling in neurodegenerative diseases.
Int J Cell Biol. 2015;2015:368584.




 http://ashpublications.org/blood/article-pdf/134/9/765/1554331/blood893594.pdf by guest on 08 M
arch 2021
